The startup develops biological treatments using single-domain antibodies for targeted therapies, focusing on pre-clinical studies to validate therapeutic applications. Their advancements in delivery methods, including topical, inhalation, injectable, and oral administration, enable tailored treatments for specific medical conditions.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional antibody therapies often suffer from limited tissue penetration, high production costs, and potential immunogenicity, hindering their effectiveness and accessibility for targeted disease treatment. Traditional delivery methods can also result in systemic side effects and reduced efficacy at the target site.
Solution
Nanogrow develops biological therapeutics based on single-domain antibodies (SdAbs) to overcome the limitations of traditional antibody therapies. Their platform leverages the unique properties of SdAbs, which are ten times smaller and simpler than conventional antibodies, allowing for better tissue penetration, enhanced stability, and easier modification. Nanogrow's approach enables targeted delivery through topical, inhalation, injectable, and oral formulations, maximizing therapeutic efficacy while minimizing systemic side effects. The company focuses on developing tailored treatments for various medical conditions, including autoimmune diseases, cancers, and inflammatory disorders.
Target Audience
Nanogrow's primary target audience includes pharmaceutical companies and research institutions focused on developing innovative therapies for autoimmune diseases, cancers, and inflammatory disorders.
Features
- Proprietary Single-domain Antibody (SdAb) platform for targeted therapies
- SdAbs are 10x smaller than conventional antibodies, improving tissue penetration
- Stable SdAb structure ensures consistent performance across delivery systems
- Versatile SdAbs allow for easy modification and fusion with other molecules
- Scalable, high-yield production across various expression systems
- Development of topical formulations for autoimmune diseases like psoriasis
- Development of inhaled formulations for respiratory diseases like asthma
- Development of injectable formulations for chronic disease management
- Development of oral formulations for inflammatory bowel diseases